Clinical Trials Logo

Clinical Trial Summary

The clinical study with UMC119-06 is designed to investigate the safety in patients with Chronic Obstructive Pulmonary Disease. This will be a dose escalation, open label, single-center study in adult with chronic obstructive pulmonary disease. UMC119-06 is ex vivo cultured human umbilical cord tissue-derived mesenchymal stem cells product which is intended for treatment of chronic obstructive pulmonary disease.


Clinical Trial Description

Chronic Obstructive Pulmonary Disease (COPD) is a leading cause of morbidity and mortality worldwide, predicted to be the third leading cause of death in adults by 2020. Patients with COPD are characterized with airflow limitation and chronic inflammation, which is caused by cigarette smoking, noxious particles or gases. These inhaled irritants will induce inflammation, emphysema and fibrosis though chronic exposure. The current pharmacological treatment of COPD is symptomatic and is mainly based on bronchodilators, such as selective β2-adrenergic agonists (short-and long-acting), anticholinergics, theophylline, or a combination of these drugs. In patients with continuing exacerbations, inhaled corticosteroids (ICSs) may be added in the form of a triple fixed dose combination inhaler that includes ICSs, long-acting β2-agonists (LABA) and inhaled long-acting muscarinic antagonists (LAMA). Although current clinical treatment strategies can improve and stabilize COPD states and quality of life, none of them are able to modify the progressive decline in lung function which is the hallmark of this disease. Therefore, development of new therapeutic modalities to improve the clinical outcomes and prognosis of COPD in adult patients is of urgent need. Among the more innovative, experimental therapies, mesenchymal stromal cells (MSCs) are proposed as a novel therapy with potential in treatment of COPD. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04206007
Study type Interventional
Source Meridigen Biotech Co., Ltd.
Contact
Status Active, not recruiting
Phase Phase 1
Start date June 11, 2020
Completion date June 30, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05539547 - Effect of NMES on Quadriceps Muscle Strength and Endurance in Patients With COPD Early Phase 1
Recruiting NCT04386590 - Manual Therapy in Addition to Pulmonary Rehabilitation in Moderate Chronic Obstructive Pulmonary Disease. Phase 2/Phase 3
Completed NCT05259280 - Observational Study of the Wellinks Solution Impact on Quality of Life and Clinical Outcomes in Patients With COPD N/A
Completed NCT03028142 - The Effects of RPL554 in Addition to Tiotropium in COPD Patients Phase 2
Completed NCT02962999 - Effect Of Ketamine Infusion In Patients With COPD Applied One Lung Ventilation Phase 4
Completed NCT02998944 - The Study of CCTM and Common Diseases N/A
Completed NCT05431218 - Association of Cathelicidin and Vitamin D Levels With the Category and Course of COPD Phase 4
Active, not recruiting NCT06269029 - Chest Mobility Exercises Versus Proprioceptive Neuromuscular Facilitation in Patients With COPD N/A
Completed NCT03020862 - Beetroot Juice - Effects on Performance in Chronic Obstructive Pulmonary Disease Patients N/A
Completed NCT03031093 - Aerosol Therapy in Obese COPD Patients. N/A
Recruiting NCT06072690 - Respiratory and Cardiovascular Alterations in Patients With Chronic Obstructive Pulmonary Disease